MANTA Registry for Vascular Large-bore Closure

NCT ID: NCT03330002

Last Updated: 2021-05-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-23

Study Completion Date

2021-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this observational post market study is to compile real world outcome data on the use of the Conformité Européenne (CE) marked MANTA Vascular Closure Device following percutaneous cardiac or peripheral procedures for large bore (10-18F ID) interventional devices.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Femoral Arteriotomy Closure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CE-marked MANTA vascular closure devices per IFU

Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.

CE-marked MANTA vascular closure device (VCD)

Intervention Type DEVICE

Compile real word data on MANTA VCD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CE-marked MANTA vascular closure device (VCD)

Compile real word data on MANTA VCD.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Per MANTA VCD Instructions for Use (IFU)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Essential Medical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicolas Van Mieghem, MD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center Rotterdam Netherlands

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Paul's Hospital

Vancouver, , Canada

Site Status

Vancouver General Health

Vancouver, , Canada

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Helsinki University Hospital

Helsinki, , Finland

Site Status

University of Turku

Turku, , Finland

Site Status

OLVG

Amsterdam, , Netherlands

Site Status

Catharina Ziekenhuis

Eindhoven, , Netherlands

Site Status

Erasmus Medical Center

Rotterdam, , Netherlands

Site Status

Luzerner Kantonsspital

Lucerne, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Denmark Finland Netherlands Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Kadakia MB, Herrmann HC, Desai ND, Fox Z, Ogbara J, Anwaruddin S, Jagasia D, Bavaria JE, Szeto WY, Vallabhajosyula P, Li R, Menon R, Kobrin DM, Giri J. Factors associated with vascular complications in patients undergoing balloon-expandable transfemoral transcatheter aortic valve replacement via open versus percutaneous approaches. Circ Cardiovasc Interv. 2014 Aug;7(4):570-6. doi: 10.1161/CIRCINTERVENTIONS.113.001030. Epub 2014 Jul 15.

Reference Type BACKGROUND
PMID: 25027520 (View on PubMed)

Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium (VARC)-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012 Nov;42(5):S45-60. doi: 10.1093/ejcts/ezs533. Epub 2012 Oct 1.

Reference Type BACKGROUND
PMID: 23026738 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PSD-212

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05409976 ACTIVE_NOT_RECRUITING NA